Cancel
About Jason Cathelyn
Jason Cathelyn is the VP of Intellectual Property, known for his leadership in intellectual property strategy at Acceleron Pharma and his previous role at Ropes & Gray in biotechnology and pharmaceutical intellectual property.
Known information
Jason Cathelyn currently serves as the Vice President of Intellectual Property. He has a distinguished background in the field, having previously held the same position at Acceleron Pharma, where he was instrumental in developing and implementing intellectual property strategies across the company’s commercial, clinical-stage, and pre-development programs. His efforts supported key legal and patent strategies for significant products such as Reblozyl (luspatercept-aamt) and sotatercept, contributing to Acceleron Pharma’s successful acquisition by Merck. Before his tenure at Acceleron Pharma, Cathelyn worked at the law firm Ropes & Gray, where he assisted clients in the biotechnology and pharmaceutical industries with various intellectual property issues. He holds a Ph.D. in Molecular Microbiology & Microbial Pathogenesis from Washington University in St. Louis, underscoring his deep expertise in the field.
About Disc Medicine
Disc Medicine develops new therapies for rare blood disorders, focusing on hematologic diseases and conducting clinical trials to evaluate drug efficacy.
Report inaccurate information
